摘要
【目的】观察罗格列酮对老年糖尿病（DM）患者内皮细胞功能的影响。【方法】46例诊断为2型DM的老年患者随机分为格列酮组（罗格列酮，4mg/d，n=23）与二甲双胍组（二甲双胍，750mg／d，n=23），连续治疗12周。另选23例年龄、性别相匹配的正常人为对照组。两组分别在治疗前、治疗3个月后，检测空腹血糖（FPG）、糖化血红蛋白（HbA1c）、一氧化氮（NO）、内皮素-1（ET-1）。肱动脉基础内径、血流介导的内皮依赖性舒张（FMD）和硝酸甘油介导的非内皮依赖性舒张（EID），并与对照组相应指标比较。【结果】罗格列酮组、二甲双胍组治疗前FPG、HbA1c、ET-1水平均明显高于正常对照组，NO水平明显低于对照组（P〈0．01）。两组治疗后FPG、HbA1c、ET-1水平均明显低于治疗前，NO水平明显高于治疗前（P〈0．01）。罗格列酮组治疗后N0水平明显高于二甲双胍组（P〈0．05）。两组治疗前与正常对照组间肱动脉基础内径无显著性差异（P〉0．05），但FMD和EID均低于对照组（P〈0．01）。治疗两组肱动脉基础内径较治疗前均无变化（P〉0．05），FMD和EID较治疗前显著升高（P〈0．05）。【结论】老年DM患者均存在内皮细胞功能受损，罗格列酮与二甲双胍均有较好的内皮细胞功能保护作用。
[Objective]To investigate the effects of rosiglitazone on endotheliocyte function in elderly patients ：suffered Type 2 diabetes. [Methods]Forty six elderly patients suffered Type 2 diabetes were divided into rosiglitazone（4mg/d） group, and metformin grouP（750mg/d）, and 23 normal elderly healthy subjects were as the control group. All patients were treated for 12 weeks. FPG, HbAlc, NO and ET-1 were measured before and after therapy. The arteria brachialis basic inner diameter, flow-mediated dilatation（FMD）and endothelium independent dilatation （EID）were measured by high-resolution ultrasound. [Results]The levels of FPG, HbAlc and ET1 in rosiglitazone and metformin group were significantly higher than those of normal control group（ P〈0.01）, and NO level in rosiglitazone and metformin group was lower than that of normal control group（ P〈0.01）. After 12 week therapy, FPG, HbAlc and ET1 in rosiglitazone and metformin group were deceased and NO was increased significantly in rosiglitazone group（ P 〈0.05）. There was no difference in arteria brachialis basic inner diameter between before and after therapy in 3 groups（ P 〉0.05）. FMD and EID were improved significantly after 12-week therapy（ P 〈0.05）. [Conclusion] Endotheliocyte function is impaired in elderly patients with Type 2 diabetes. Rosiglitazone and metformin can be used to treat the elderly patients with Type 2 diabetes for their role of protecting endotheliocyte function.
出处
《医学临床研究》
CAS
2009年第5期786-788,共3页
Journal of Clinical Research
